Kelly Andrzejewski
Neurology · Rochester, NYNPI 1295051886
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $102,049 of the $129,099 with a category attached, or 79.0%. Teva Pharmaceuticals USA, Inc. accounts for 76.6% of it on its own, with 25 other manufacturers making up the rest. Among neurology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $367.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$99K
- AbbVie$16K
- Lundbeck LLC$5K
- Boston Scientific$4K
- Acorda Therapeutics, Inc$3K
- Medtronic$2K
- plus $1K from 20 others
Across 240 payments — averaging $1952.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$195K
- Neurocrine Biosciences, Inc.$180K
- Boston Scientific$45K
- Teva Pharmaceuticals USA, Inc.$30K
- H. Lundbeck A S$17K
- Lundbeck LLC$1K
What the payments were for
- Consulting fees$11,3189%
- Speaking & faculty fees$102,04979%
- Travel & lodging$7,8166%
- Food & beverage$7,3596%
- Education$5580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 172 | $98,953 |
| AbbVie | 45 | $15,720 |
| Lundbeck LLC | 9 | $4,789 |
| Boston Scientific | 29 | $3,523 |
| Acorda Therapeutics, Inc | 7 | $2,991 |
| Medtronic(2 entities) | 29 | $1,828 |
| MDD US Operations, LLC | 17 | $292 |
| Abbott | 12 | $234 |
| CSL Behring | 3 | $98 |
| Supernus Pharmaceuticals, Inc. | 3 | $72 |
| Ipsen Biopharmaceuticals, Inc | 3 | $71 |
| Amneal Pharmaceuticals LLC | 3 | $69 |
| Merz Pharmaceuticals, LLC | 2 | $67 |
| Neurocrine Biosciences, Inc. | 3 | $55 |
| Grifols USA, LLC | 2 | $51 |
| Livanova USA, Inc. | 2 | $47 |
| Greenwich Biosciences, Inc. | 1 | $31 |
| Acadia Pharmaceuticals Inc | 1 | $30 |
| SK Life Science, Inc. | 1 | $27 |
| AstraZeneca | 1 | $26 |
| UCB, Inc. | 1 | $25 |
| Revance Therapeutics, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Neurelis, Inc. | 1 | $20 |
| PTC Therapeutics, Inc. | 1 | $19 |
| GE HealthCare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$52,919
- AUSTEDO$43,198
- Duopa$15,020
- NORTHERA$4,642
- GENERAL DBS$2,907
- INBRIJA$2,825
- ACTIVA$838
- PERCEPT PC BRAINSENSE$267
- ACTIVA PC$110
- VERCISE$106
How this compares
$129,099 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 80 | $1,314,064 |
| Austedo XrDeutetrabenazine | 47 | $536,207 |
| NuplazidPimavanserin Tartrate | 58 | $322,229 |
| RytaryCarbidopa/Levodopa | 143 | $242,834 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 574 | $41,818 |
| Rasagiline Mesylate | 82 | $18,219 |
| Entacapone | 53 | $16,105 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 201 | $9,099 |
| OngentysOpicapone | 13 | $7,624 |
| Rivastigmine | 27 | $5,964 |
| Carbidopa | 19 | $5,587 |
| AmantadineAmantadine Hcl | 80 | $5,480 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 12 | $3,896 |
| Primidone | 74 | $3,357 |
| Clonazepam | 121 | $2,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $98,953 | $1,850,271127 claims |
| Acadia Pharmaceuticals IncNuplazid | $30 | $322,22958 claims |
| Amneal Pharmaceuticals LLCRytary | $69 | $242,834143 claims |
| Neurocrine Biosciences, Inc.Ongentys | $55 | $7,62413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.
Other neurology in Rochester
- Jacob DominikRochester$216K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.